GSK Bexxar No Longer Rituxan Dependent For Non-Hodgkin's Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will promote Bexxar as a "true second-line therapy" in patients who have relapsed after any regimen containing Rituxan and/or chemotherapy. Previously, patients had to be refractory to rituximab prior to considering Bexxar as a therapeutic option.